Novosound, which is based in Scotland and has designed and developed the first ultrasonic blood pressure monitor, has announced the funding of £2 million from Par Equity and other prominent investors like the University of the West of Scotland, Scottish Enterprise, and Kelvin Capital.
Novosound has said that this funding will help the company to commercialize its innovative ultrasonic blood pressure monitor, which does not require cuffs like present ultrasonic machines and can be embedded into smartwatches, smart rings, etc., and since Scotland is at the forefront of ultrasound innovation, the company is proud to disrupt the field positively with high accuracy.
Dave Hughes is the Chief Executive Officer at Novosound, and he founded this company around 5 years ago with a vision of having an Integrated Ultrasound System everywhere, from hospitals to homes, so that humankind gets the full benefit of this technology. Previously, he worked at the University of the West of Scotland as the Research Theme Leader in Ultrasound Imaging.
Novosound has already created wireless wearable ultrasound machines that are commercialized and have been used for digital health monitoring and other medical applications by professionals for a long time. As we know, around half a billion people are currently suffering from Cardiovascular diseases globally, and only in the year 2021, we saw around 20 million deaths as per the World Heart Federation. With this innovation and commercialization, the company is planning to make a huge impact on society.
Swastik Saraf is the Founder and Managing Editor of TheMedSector. With a background in data journalism and healthcare research, he specializes in aggregating public health metrics, analyzing institutional data, and mapping out regional healthcare infrastructure. Swastik leads the data compilation team at TheMedSector, ensuring all directory tracking is built on verified primary sources before undergoing formal clinical review.
